Skip to main content

Taboolacom Ltd

For the period ended Dec 31, 2023. Filed Feb 28, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 28, 2024

TBLA$2.02-6.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 8. Consolidated Statements of Cash Flows

Year ended December 31,
202320222021
Cash flows from operating activities
Net loss$(82,040)$(11,975)$(24,948)
Adjustments to reconcile net loss to net cash flows provided by operating activities:
Depreciation and amortization96,51291,22153,111
Share-based compensation expenses64,33174,921127,957
Net loss (gain) from financing expenses(816)4,476(2,320)
Revaluation of the Warrants liability(627)(24,471)(22,656)
Amortization of loan and credit facility issuance costs1,6192,009402
Amortization of premium and accretion of discount on short-term investments, net(914)(679)—
Loss from disposal of property and equipment1,571——
Change in operating assets and liabilities:
Increase in trade receivables, net(49,599)(11,242)(40,113)
Decrease (increase) in prepaid expenses and other current assets and long-term prepaid expenses5,934(10,785)(64,923)
Increase (decrease) in trade payables36,563(16,825)23,862
Increase (decrease) in accrued expenses and other current liabilities and other long-term liabilities25,202(21,932)16,182
Decrease in deferred taxes, net(15,496)(17,329)(1,581)
Change in operating lease right of use assets16,83015,52814,529
Change in operating lease liabilities(14,697)(19,433)(15,981)
Net cash provided by operating activities84,37353,48463,521
Cash flows from investing activities
Purchase of property and equipment, including capitalized internal-use software(32,133)(34,914)(39,070)
Cash paid in connection with acquisitions, net of cash acquired—(7,981)(583,457)
Proceeds from (investment in) restricted deposits(730)912,067
Proceeds from maturities of short-term investments114,49429,624—
Purchase of short-term investments(21,991)(126,381)—
Net cash provided by (used in) investing activities59,640(139,561)(620,460)
Cash flows from financing activities
Exercise of options and vested RSUs6,9538,38710,018
Issuance of Ordinary shares, net of offering costs——285,378
Payment of tax withholding for share-based compensation expenses(3,804)(5,751)(6,152)
Repurchase of Ordinary shares(55,513)——
Proceeds from long-term loan, net of debt issuance costs——288,750
Repayment of long-term loan(82,250)(64,264)(750)
Costs associated with entering into a revolving credit facility—(1,245)—
Issuance of Warrants——53,883
Net cash provided by (used in) financing activities(134,614)(62,873)631,127
Exchange rate differences on balances of cash and cash equivalents816(4,476)2,320
Increase (decrease) in cash and cash equivalents10,215(153,426)76,508
Cash and cash equivalents - at the beginning of the period165,893319,319242,811
Cash and cash equivalents - at the end of the period$176,108$165,893$319,319
Year ended December 31,
202320222021
Supplemental disclosures of cash flow information:
Cash paid during the year for:
Income taxes$18,011$28,798$15,475
Interest$18,488$20,712$1,125
Non-cash investing and financing activities:
Purchase of property and equipment, including capitalized internal-use software$639$1,657$1,120
Share-based compensation included in capitalized internal-use software$2,253$1,932$783
Creation of operating lease right-of-use assets$11,730$17,269$4,520
Fair value of Ordinary shares issued as consideration of the acquisition$—$—$157,689
Issuance of Ordinary shares and Non-voting Ordinary shares related to Commercial agreement$288,063$—$—

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.